Nosopharm Signs an Agreement with Evotec to Accelerate the Development of Antibiotics

 Nosopharm Signs an Agreement with Evotec to Accelerate the Development of Antibiotics

Nosopharm Signs an Agreement with Evotec to Accelerate the Development of Antibiotics

Shots:

  • Nosopharm and Evotec collaborated to advance Nosopharm’s NOSO-502 to clinical stage and to develop second-generation Odilorhabdin (ODLs) for hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP), under the name NOSO-2G
  • The collaboration initially focuses on Chemistry, Manufacturing and Control (CMC) and Clinical Trial Application (CTA)-enabling and filing activities regarding NOSO-502 for the onset of P-I study of NOSO-502 for the treatment of cUTI & cIAI
  • NOSO-502 belongs to the class of ODLs inhibiting bacterial ribosomes and is intended to treat nosocomial infections by Enterobacteriaceae with its expected CTA-filing and initiation of clinical study in 2021

Click here to read full press release/ article | Ref: Nosopharm | Image: Evotec

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post